Weil Advises CBC Group on its Acquisition of China-Based Yaneng Bioscience

Weil represented CBC Group as the lead investor on the consortium aspects in connection with its acquisition of approximately 43% equity in Yaneng Bioscience (Shenzhen) Co., Ltd. (Yaneng) for an aggregate consideration of approximately $390 million. The underlying transaction documents with Yaneng and existing shareholders were signed on September 30, 2021.

CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment firms in Asia.

Headquartered in Shenzhen, China, Yaneng is a leading biotechnology company specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and testing instruments.

The Weil team was led by China Private Equity and M&A partner Charles Ching, and included counsel Kenny Yu and associate Carol Jia.